background
human
bocaviru
hbov
newli
identifi
human
parvoviru
hbov
associ
upper
lower
respiratori
tract
infect
gastroenter
children
littl
known
seroepidemiolog
hbov
popul
caribbean
method
crosssect
studi
conduct
univers
hospit
west
indi
kingston
jamaica
blood
sampl
collect
pediatr
patient
test
presenc
hbovspecif
antibodi
use
viruslikeparticl
base
enzymelink
immunosorb
assay
elisa
result
hbovspecif
antibodi
found
present
sampl
collect
pediatr
popul
seropreval
hbov
highest
year
old
seroepidemiolog
profil
suggest
children
expos
hbov
first
two
year
life
jamaica
conclus
hbov
infect
common
children
jamaica
hbov
seropreval
rate
caribbean
similar
previous
report
area
world
lower
respiratori
tract
infect
commonli
caus
virus
one
lead
caus
morbid
mortal
children
worldwid
unit
state
approxim
children
year
hospit
first
year
life
due
viral
lower
respiratori
tract
infect
develop
countri
problem
even
larger
million
children
die
year
due
acut
respiratori
ill
recent
viral
lower
respiratori
infect
children
attribut
respiratori
syncyti
viru
rsv
parainfluenzaviru
adenoviru
influenza
virus
yet
etiolog
major
lower
respiratori
tract
diseas
thought
viral
around
case
etiolog
identifi
agent
last
year
advanc
molecular
detect
genom
amplif
led
discoveri
mani
new
virus
includ
human
metapneumoviru
hmpv
human
coronavirus
sarscov
ki
wu
polyomavirus
human
bocaviru
hbov
herein
examin
novel
respiratori
viru
hbov
parvoviru
first
describ
alland
et
al
found
associ
respiratori
tract
diseas
gastroenter
children
differ
type
hbov
isol
infect
primarili
respiratori
epithelium
infect
gastrointestin
tract
clinic
featur
associ
detect
infect
includ
fever
rhinorrhea
cough
wheez
gastroenter
unit
state
hbov
viral
dna
detect
pcr
nasopharyng
swab
children
new
ct
respiratori
tract
diseas
test
neg
rsv
influenza
b
viru
parainfluenza
virus
adenovirus
asymptomat
control
subject
suggest
possibl
causal
role
viru
respiratori
tract
diseas
addit
seroepidemiolog
studi
new
ct
found
children
antibodi
hbov
age
year
suggest
exposur
hbov
nearli
univers
earli
childhood
yet
littl
known
hbov
develop
world
studi
sought
determin
whether
hbov
infect
present
caribbean
popul
attempt
elucid
possibl
differ
hbov
epidemiolog
tropic
resourc
poor
set
use
recent
develop
elisa
hbov
examin
hospit
nonhospit
children
age
year
present
care
univers
hospit
west
indi
kingston
jamaica
june
august
purpos
studi
gener
estim
exposur
hbov
caribbean
compar
hospit
nonhospit
children
differ
age
attempt
identifi
subpopul
might
risk
increas
hbov
exposur
studi
approv
yale
univers
human
investig
committe
univers
hospit
west
indi
investig
committe
written
inform
consent
obtain
parent
guardian
behalf
minor
children
particip
involv
studi
crosssect
studi
conduct
univers
hospit
west
indi
locat
kingston
jamaica
june
august
jamaica
develop
countri
popul
million
gross
nation
incom
per
captia
usd
infant
mortal
rate
per
live
birth
univers
hospit
west
indi
academ
medic
center
jamaica
serv
primari
public
tertiari
care
center
jamaica
inclus
criteria
studi
includ
pediatr
patient
age
year
age
present
care
univers
hospit
total
serum
sampl
collect
pediatr
patient
popul
sampl
collect
via
fingerstick
method
use
stat
sampler
tm
collect
system
children
present
routin
care
vaccin
well
child
clinic
remain
sampl
collect
hospit
clinic
chemistri
laboratori
leftov
venipunctur
clinic
sampl
includ
inpati
pediatr
unit
pediatr
subspecialti
clinic
neonat
intens
care
pediatr
trauma
newborn
special
care
time
collect
inform
symptomatolog
collect
purpos
studi
screen
hbovspecif
iggantibodi
repres
previou
viral
exposur
finger
stick
venou
blood
sampl
use
shown
similar
igg
rate
elisa
shown
vejtorp
leerhoy
collect
blood
sampl
centrifug
rpm
minut
blood
serum
collect
store
sampl
store
univers
hospit
west
indi
degre
celsiu
prior
ship
yale
univers
school
medicin
detect
hbovspecif
antibodi
human
serum
hbov
viru
like
particlebas
elisa
elisa
develop
kahn
et
al
use
detect
hbovspecif
antibodi
detail
descript
found
elsewher
briefli
elisa
use
viru
like
particl
vlp
compos
gene
hbov
vlp
creat
kahn
et
al
shown
high
reactiv
human
antibodi
hbov
therefor
optim
use
elisa
hbov
vlp
obtain
dr
peter
tattersal
yale
univers
school
medicin
kahn
et
al
elisa
protocol
optim
use
given
studi
sampl
first
sampl
run
variou
dilut
determin
adequ
dilut
use
assay
dilut
chosen
optim
reactiv
hbov
vlp
given
elisa
next
posit
neg
control
identifi
compar
sampl
known
hbov
infect
identifi
posit
neg
control
use
assay
final
sampl
run
dilut
read
optic
reader
optic
densiti
nm
order
determin
cutoff
point
classifi
sampl
seroposit
seroneg
elisa
valu
taken
oper
separ
group
mean
cutoff
previous
publish
kahn
et
al
next
mean
standard
deviat
valu
calcul
cut
point
classifi
sampl
seroposit
seroneg
calcul
mean
plu
three
standard
deviat
calcul
neg
valu
set
zero
base
calcul
serum
specimen
neg
hbov
defin
dilut
data
analyz
use
spss
standard
error
proport
calcul
use
standard
statist
analysi
subject
without
serolog
evid
past
hbov
infect
compar
respect
hospit
statu
age
group
use
chisquar
test
categor
variabl
ttest
continu
variabl
multivari
logist
regress
use
determin
signific
final
model
test
twotail
critic
alpha
defin
statist
signific
overal
serum
specimen
seroposit
hbov
antibodi
proport
seroposit
vari
age
group
figur
although
newborn
birth
seroposit
hbov
proport
decreas
six
month
age
six
month
age
proport
seroposit
subject
rapidli
rebound
age
month
children
seroposit
age
signific
predictor
hbov
exposur
children
hbov
seroposit
children
older
averag
age
month
hbov
seroneg
children
averag
age
month
order
determin
hospit
associ
hbov
exposur
character
subgroup
hospit
children
inpati
pediatr
ward
compar
nonhospit
children
well
child
clinic
never
previous
hospit
comparison
children
subspecialti
clinic
neonat
intens
care
pediatr
trauma
special
care
exclud
basi
inabl
determin
previou
hospit
histori
neonat
month
also
exclud
premis
major
posit
valu
age
group
would
repres
matern
antibodi
previou
hbov
exposur
hospit
prove
significantli
associ
hbov
exposur
hospit
children
versu
nonhospit
children
test
seroposit
hbov
p
howev
hospit
children
significantli
older
averag
age
month
versu
month
nonhospit
children
multivari
analysi
age
subject
prove
statist
signific
find
seroepidemiolog
studi
conduct
mani
develop
countri
screen
presenc
hbov
viru
appear
worldwid
distribut
date
report
hbov
develop
world
studi
first
seroepidemiolog
studi
show
hbov
antibodi
present
caribbean
popul
find
greater
jamaican
children
expos
hbov
age
month
seroepidemiolog
find
show
high
rate
hbov
antibodi
first
month
life
declin
nadir
around
month
rebound
seroposit
around
month
declin
antibodi
infant
less
month
age
repres
wane
matern
acquir
antibodi
observ
respiratori
virus
rsv
human
metapneumoviru
declin
overlap
exposur
hbov
infanc
earli
childhood
age
sole
predictor
associ
presenc
hbov
antibodi
studi
popul
hbov
exposur
common
popul
therefor
children
increas
likelihood
exposur
age
increas
enrol
healthi
hospit
children
effort
character
differ
exposur
popul
adequ
estim
hbov
seroepidemiolog
overal
popul
sinc
hbov
seroepidemiolog
subspecialti
clinic
hospit
patient
may
repres
overal
seroposit
rate
popul
enrol
healthi
children
prospect
manner
seroepidemiolog
healthi
vs
hospit
children
differ
hospit
children
expos
hbov
healthi
children
found
directli
relat
age
popul
therefor
sinc
differ
hospit
healthi
children
due
age
feel
comfort
includ
children
studi
overal
estim
seroepidemiolgoy
popul
hbov
seroepidemiolog
preval
studi
shown
evid
widespread
exposur
viru
caus
role
hbov
respiratori
tract
diseas
still
investig
definit
evid
difficult
obtain
without
vitro
cultur
system
anim
model
one
recent
success
report
propag
hbov
cell
cultur
techniqu
proven
difficult
replic
absenc
definit
evid
compar
studi
use
suggest
caus
role
hbov
acut
infect
howev
studi
complic
fact
hbov
often
codetect
respiratori
virus
make
difficult
draw
conclus
pathogen
one
studi
alland
et
al
show
symptomat
patient
acut
wheez
test
posit
hbov
dna
pcr
absenc
virus
known
caus
respiratori
diseas
suggest
possibl
caus
role
hbov
acut
wheez
three
studi
kesebir
fri
maggi
also
tri
address
whether
hbov
infect
associ
respiratori
tract
symptom
studi
report
hbov
dna
frequent
found
patient
acut
respiratori
tract
symptom
asymptomat
control
limit
studi
includ
lack
serial
sampl
lack
detect
viral
dna
pcr
inabl
verifi
elisa
find
neutral
assay
current
one
major
obstacl
studi
epidemiolog
biolog
hbov
lack
reagent
specif
infecti
viru
monospecif
antihbov
antibodi
therefor
unabl
verifi
elisa
neutral
assay
instead
use
accept
statist
method
correct
cutoff
valu
elisa
regrett
studi
perform
prior
discoveri
hbov
specif
subtyp
elisa
use
specif
individu
hbov
subtyp
rather
hbovspecif
antibodi
gener
make
find
statement
specif
hbov
subtyp
conclus
first
studi
hbov
seroepidemiolog
caribbean
popul
show
hbov
common
viru
infect
children
within
first
year
life
find
hbov
seroepidemiolog
jamaica
similar
report
area
world
reinforc
notion
hbov
worldwid
distribut
